Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research
Open accessThe DOI matches its Crossref record; 148 of the 151 references it cites were found in a registry or an index.
Abstract
Phosphatidylinositol-3-kinase (PI3K) enzymes, producing signaling phosphoinositides at plasma and intracellular membranes, are key in intracellular signaling and vesicular trafficking pathways. PI3K is a family of eight enzymes divided into three classes with various functions in physiology and largely deregulated in cancer. Here, we will review the recent evidence obtained during the last 5 years on the roles of PI3K class I, II and III isoforms in tumor biology and on the anti-tumoral action of PI3K inhibitors in preclinical cancer models. The dependency of tumors to PI3K isoforms is dictated by both genetics and context (e.g., the microenvironment). The understanding of class II/III isoforms in cancer development and progression remains scarce. Nonetheless, the limited available data are consistent and reveal that there is an interdependency between the pathways controlled by all PI3K class members in their role to promote cancer cell proliferation, survival, growth, migration and metabolism. It is unknown whether this feature contributes to partial treatment failure with isoform-selective PI3K inhibitors. Hence, a better understanding of class II/III functions to efficiently inhibit their positive and negative interactions with class I PI3Ks is needed. This research will provide the proof-of-concept to develop combination treatment strategies targeting several PI3K isoforms simultaneously.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 3 PI3K cross-regulations and possible class I, II and III PI3Ks combination targeting in cancer. (A). PI3K class I isoform cross-regulations upon inhibition of one isoform. Thick lines = primary inhibition, dashed arrows = subsequent regulations. (B). PI3K cross-regulations among different classes are still poorly understood but based on this knowledge, new therapeutic strategies arise to overcome treatment resistance in cancer. (i) All PI3K classes directly or indirectly regulate mTORC1 activity. Class I PI3Kα, β, γ and δ phosphorylate PIP2 into PIP3 which allow the recruitment of PDK1 to the plasma membrane. PDK1 then activates AKT which subsequently enhances mTORC1 activity. The latter can inhibit PI3K in a negative feedback. Class II PI3K-C2α activates mTORC1 and favors its translocation to the plasma membrane via Raptor association to PIP2 [135,140]. On the contrary, PI3K-C2β produces PI(3,4)P2, allowing the link of 14-3-3 which represses mTORC1 [136]. Loss of PI3K-C2γ is responsible for an mTOR activation [96]. Vps34 allows the amino acid activation of the phospholipase D1 (PLD1) which then translocates to the lysosome and stimulates mTORC1 activity [141] but can also inhibit PDK1 sumoylation which results in less AKT and mTOR activation. (ii) Vps34 regulates autophagy while class I PI3Ks modulate proliferation. Both mechanisms are important for cancer cell survival. (iii) Class III PI3K Vps34 can indirectly modulate PI3Kβ activity by allowing PTEN relocalization to intracellular PI(3)P vesicles whose level is regulated by Vps34 [138]. (iv) Vps34 inhibition triggers PD-L1 expression [118] while PI3Kδ induces the expression of PD-1 in CD8+ cells [139]. “ON” means that the protein is activated while “OFF” means it is inactivated or absent. Red inhibition or activation lines correspond to possible combination therapies that could be inhibitory or activatory. Of note, all these pathways were demonstrated in different cell types and contexts; the large significance of these data is currently unknown.](https://figures.cochat.ai/paper-figures/5ec3a62f19a64e1a9c6e572662090fa9/targeting-class-i-ii-iii-pi3ks-in-cancer-therapy-recent-advances-in-tumor-figure-3.jpg)

![Figure 2 Engagement of class I PI3K isoforms in cancer depending on genetic alterations or context-dependent activation. Tumors’ specific dependency on PI3K inhibitors is mainly based on (i) genetic alterations and (ii) context-dependent activation of isoforms. (i) Oncogenic activation of PI3Kα catalytic domain leads to PI3Kα sensitivity while PI3Kβ gene amplification or PTEN loss is responsible for PI3Kβ inhibitors’ efficacy. RAS oncogenic activation directly couples with PI3Kα,γ or δ isoforms (but not PI3Kβ) [49,50]. (ii) GSK3β-dependent inhibitory phosphorylation of PTEN could possibly increase sensitivity to PI3Kα or PI3Kβ inhibitors. Inflammatory context (e.g., TNFα [17], GPCR ligand S1P [43]) activates PI3Kα or PI3Kβ/PI3Kγ, respectively. Mechanical signals possibly promote PI3Kβ activation [40]. Increased expression of PI3Kγ promotes PI3K activation [51].](https://figures.cochat.ai/paper-figures/41b41a4b38384f7caace314a0d0cff93/targeting-class-i-ii-iii-pi3ks-in-cancer-therapy-recent-advances-in-tumor-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway is a major downstream signaling cascade of EGFR and represents an important bypass mechanism contributing to resistance to cetuximab and panitumumab [40,41,42,43,44].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yue, D., & Sun, X. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0960-8 · Cited by 40
RetractedThe emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767 · cited 2×
“This therapeutic strategy was supported by the fact that, even though all class I PI3Ks catalyze the same reaction, they show distinct relevance in each organ and in each tumor type [2].”
BackgroundSelf-citationIdelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314583 · Cited by 1,069
Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis
Takahashi, Y., Coppola, D., Matsushita, N., Cualing, H. D., Sun, M., Sato, Y., Liang, C., Jung, J. U., Cheng, J. Q., Mul, J. J., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1634 · Cited by 927
André, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I. A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.011 · Cited by 624
Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice
Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B., Nye, E., Stamp, G., Alitalo, K., & Downward, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.051 · Cited by 589
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
PI3K isoforms in cell signalling and vesicle trafficking
Bilanges, B., Posor, Y., & Vanhaesebroeck, B. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0129-z · Cited by 525
Cited by
Li, H., Wen, X., Ren, Y., Fan, Z., Zhang, J., He, G., & Fu, L. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02072-1 · Cited by 125
Regulation of PI3K signaling in cancer metabolism and PI3K-targeting therapy
Han, B., Lin, X., & Hu, H. (2024) · Translational Breast Cancer Research · doi:10.21037/tbcr-24-29 · Cited by 53
Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers
Shan, K. S., Bonano-Rios, A. M., Theik, N. W. Y., Hussein, A. M., & Blaya, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041973 · Cited by 35
Isoform-selective targeting of PI3K: time to consider new opportunities?
Cirillo, D., Diceglie, M., & Nazaré, M. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.06.002 · Cited by 24
Breast Cancer: Molecular Pathogenesis and Targeted Therapy
Samad, M. A., Ahmad, I., Khan, M. R., Suhail, M., Zughaibi, T. A., Al-Abbasi, F. A., Alhosaini, K. A., Khan, M. S., Kumer, A., & Tabrez, S. S. M. (2025) · MedComm · doi:10.1002/mco2.70404 · Cited by 34
Metadata
- Authors
- Thibault, B., Ramos-Delgado, F., & Guillermet-Guibert, J.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Centre de Recherches en Cancérologie de Toulouse, Université de Toulouse, Inserm, CNRS, 31037 Toulouse, France
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2023-01-27
- Volume
- 15
- Issue
- 3
- Pages
- 784
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC9913247
- OpenAlex
- W4318485540
- Cited by
- 40
- References
- 151
- Citations by year
- 2026: 14 · 2025: 12 · 2024: 12 · 2023: 2
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- Funders
- ANR JCJC program Radiance (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
- MSCA-ITN/ETN PhD-PI3K (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
- IUCT-O/ICR translational program (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
- Ligue Régionale Contre Le Cancer (2020, 2021) (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
- Fondation Arc (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
- ANR (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
- Laboratoire d’Excellence (Projet-ANR-18-CE14-0013, 675392, PJA2021060003932)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- phosphatidylinositol 3-kinase, PI3K inhibitors, isoform-selective inhibitors, cancer therapy, tumor microenvironment, tumor cell proliferation, cancer metabolism, combination therapy, PI3K signaling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research. https://app.cochat.ai/papers/10.3390/cancers15030784
- The paper
- Thibault, B., Ramos-Delgado, F., & Guillermet-Guibert, J. (2023). Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research. Cancers. https://doi.org/10.3390/cancers15030784
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.